BMS-986278

DRUG16 trials

Sponsors

Bristol-Myers Squibb Services Unlimited Company, Bristol-Myers Squibb

Conditions

Healthy ParticipantsHealthy VolunteersHepatic ImpairmentIdiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)Kidney Failure, ChronicProgressive Pulmonary FibrosisProgressive pulmonary fibrosis and Idiopathic pulmonary fibrosis

Phase 1

A Study of Experimental Medication BMS-986278 Given to Healthy Participants

CompletedNCT03429933

Bristol-Myers SquibbHealthy Participants

Start: 2018-02-07End: 2019-03-02Updated: 2019-10-01

An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants

CompletedNCT03712540

Bristol-Myers SquibbHealthy Participants

Start: 2018-09-06End: 2018-11-08Updated: 2019-06-12

A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants

CompletedNCT03981094

Bristol-Myers SquibbIdiopathic Pulmonary Fibrosis (IPF)

Start: 2019-05-10End: 2019-07-30Updated: 2020-05-15

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

CompletedNCT05684289

Bristol-Myers SquibbHealthy Participants

Start: 2023-01-03End: 2023-05-02Updated: 2023-08-24

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants

CompletedNCT05805904

Bristol-Myers SquibbHealthy Volunteers

Start: 2023-03-29End: 2023-05-23Updated: 2023-09-18

A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants

CompletedNCT05932303

Bristol-Myers SquibbHealthy Participants

Start: 2023-07-12End: 2023-10-23Updated: 2023-10-30

A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants

CompletedNCT05985590

Bristol-Myers SquibbHealthy Volunteers

Start: 2023-08-18End: 2023-12-11Updated: 2024-01-24

Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

CompletedNCT06425198

Bristol-Myers SquibbHealthy Participants, Hepatic Impairment

Start: 2024-06-10End: 2024-12-30Updated: 2025-01-22

A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

CompletedNCT06723535

Bristol-Myers SquibbHealthy Volunteers, Kidney Failure, Chronic, Renal Impairment

Start: 2024-12-07End: 2025-09-19Updated: 2025-10-14

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants

CompletedNCT06746402

Bristol-Myers SquibbHealthy Volunteers

Start: 2025-02-10End: 2025-09-11Updated: 2025-10-06

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

CompletedNCT07422298

Bristol-Myers SquibbHealthy Volunteers

Start: 2026-02-19End: 2026-06-14Updated: 2026-08-03

Phase 2

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

CompletedNCT04308681

Bristol-Myers SquibbPulmonary Fibrosis

Start: 2020-07-29End: 2023-09-22Updated: 2026-02-03

Phase 3

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Active, not recruitingNCT06003426

Bristol-Myers SquibbIdiopathic Pulmonary Fibrosis

Start: 2023-09-14End: 2027-06-04Updated: 2026-03-24

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Active, not recruitingNCT06025578

Bristol-Myers SquibbProgressive Pulmonary Fibrosis

Start: 2023-10-25End: 2027-12-27Target: 1057Updated: 2026-04-23

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

Not yet recruitingNCT07441408

Bristol-Myers SquibbPulmonary Fibrosis

Start: 2026-12-16End: 2030-03-30Target: 2380Updated: 2026-08-14

IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis

Not yet recruitingCTIS2025-522373-10-00

Bristol-Myers Squibb Services Unlimited CompanyProgressive pulmonary fibrosis and Idiopathic pulmonary fibrosis

Target: 253Updated: 2026-06-18

Related Papers

Biomarker profiles in idiopathic and progressive pulmonary fibrosis after LPA1 antagonism: exploratory analysis from a phase 2 trial of admilparant

Respiratory Research2026-07-15

Design and Rationale of a Phase 3 Trial for Admilparant (BMS-986278), an Oral Lysophosphatidic Acid Receptor 1 Antagonist, in Patients With Progressive Pulmonary Fibrosis: ALOFT-PPF

American Journal of Respiratory and Critical Care Medicine2025-05-01

Design and Rationale for a Phase 3 Trial of Admilparant (BMS-986278), An Oral Lysophosphatidic Acid Receptor 1 Antagonist, in Patients With Idiopathic Pulmonary Fibrosis: ALOFT-IPF

American Journal of Respiratory and Critical Care Medicine2025-05-01

Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis.

2025-04-081 citations

Efficacy and Safety of Admilparant, an LPA <sub>1</sub> Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial

American Journal of Respiratory and Critical Care Medicine2024-10-1132 citations

RCT Abstract - BMS-986278 for progressive pulmonary fibrosis (PPF): results from a phase 2 randomized controlled trial

2023-09-094 citations

First-in-human evaluation of 18F-BMS-986327 as a novel PET tracer to assess lysophosphatidic acid receptor 1 (LPA1) target engagement in the lung

2022-09-04

LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis

Respiratory Research2022-03-1854 citations

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA<sub>1</sub>) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

BMJ Open Respiratory Research2021-12-0150 citations

Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA<sub>1</sub>) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases

Journal of Medicinal Chemistry2021-10-2853 citations